Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quantum BioPharma Ltd C.HUGE


Primary Symbol: C.QNTM Alternate Symbol(s):  QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.


CSE:QNTM - Post by User

Comment by DavidRosenbergon Oct 02, 2021 4:16pm
74 Views
Post# 33957812

RE:RE:RE:RE:RE:RE:Don’t take it the wrong way

RE:RE:RE:RE:RE:RE:Don’t take it the wrong way
Mil_Man54 wrote: Don't be patronizing Rosenberg......it's ignorant of you to attempt to sway readers into thinking that I do not want FSD to succeed which translates to me and thousands of other investors getting our money back......you are trying to portray us as these bitter investors who want FSD to burn to the ground and fail at all costs.......and you being the sole source of reason and hope on this board......give us a break.....you are an FSD and AD promoter and will post anything to try and mislead investors and try and discredit those of us who call you out......the truth is FSD has a pattern to their failures and guess what....it's repeating itself again.....dilution, hype, failure, move on to the next scheme.......we're in the hype phase right now......so we'll see how this plays out.....but don't think to presume what are intentions are......we've already made it clear.....protect our investment if we can and ensure potentisal investors are aware of the truth and call out pumpers......

DavidRosenberg wrote:
Mil_Man54 wrote: Rosenberg just can't help himself from trying to equate FSD with ELYM.....and it's not FSD 201's reputation that is of concern....it's FSD Pharms's reputation that's the concern and it's not good..... it would even be fair say it's toxic......if time will tell then I suggest you give it that time and stop posting things like this.....

DavidRosenberg wrote:
Mil_Man54 wrote:
DavidRosenberg wrote: We are all in the same boat together and all want the same thing

they got the two novel drugs from lucid to promote and FSD 201 


FSD 201, as Walter put it, is collecting dust on the shelf becuase you know, the trials were cancelled and all that money spent for them just evaporated.....and there is nothing to promote with Lucid until they actually do something.....so right now all we have is promotional hype based on wishful thinking.....
 



Yes maybe doing PEA on Covid19 wasn't the best idea

Results from $ELYM trials might dictate which way FSD 201 goes if negative results from ELYM it could affect FSD 201's reputation as a drug for those indications.

As for Lucid they have 2 drugs one for depression and one different one for Multiple Sclerosis which are novel, meaning totally new nobody else has.

UHN has licensing patent for that via LUCID so that's where the originality and uniqueness comes from.

Anyways time will tell , good night Milman and others


 


 

 


Not only FSD reputation but all the board members and AD equally want to see it succeed 
Sorry you are hurtful towards FSD trying to improve and grow 

only time will tell if they succeed or fail , hopeuflly succeed





Updating investors on news and interviews is protecting investors so they can keep and be informed on developments
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse